JPMorgan Downgrades Jounce Therapeutics (JNCE) to Underweight

November 14, 2018 4:57 AM

JPMorgan analyst Cory Kasimov downgraded Jounce Therapeutics (NASDAQ: JNCE) from Neutral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found